Core Viewpoint - Johnson & Johnson's CEO expresses optimism about the future of pharmaceutical innovation in the U.S. despite challenges such as tariffs on imported drugs and cuts in research funding [1][2] Company Investment and Manufacturing - Johnson & Johnson plans to invest over $55 billion to build four manufacturing plants in the U.S., with a factory already under construction in North Carolina [3] - The company has maintained a manufacturing presence in the U.S. since its inception and aims to create significant middle-class jobs in various fields including robotics and cell therapy [3] Regulatory Environment and Drug Development - The Trump administration announced a 100% tariff on branded or patented pharmaceutical products entering the U.S., effective October 1, but this will not affect companies building drug manufacturing plants domestically [2] - Johnson & Johnson has recently received FDA approval for new drugs, including treatments for myeloma and bladder cancer, highlighting the company's ongoing commitment to innovation [4] Industry Strength and Talent - The CEO emphasizes the strength of the U.S. life sciences industry, citing the presence of universities, research institutions, and capital markets as key elements for continued leadership in healthcare innovation [4]